These remissions – minimal residual disease/operational cure – are sustained even after discontinuation of IFN-α2 for approximately 30 months (longest follow-up). IFN-α2 is efficacious and ...

A Yale School of Medicine team has created lists of criteria to help clinicians determine when next-generation sequencing ...

This book is an outstanding resource that includes a discussion of both classical myeloproliferative neoplasms, such as essential thrombocythemia, polycythemia vera and myelofibrosis, and also less ...

A new thesis from Karolinska Institutet shows the effectiveness of flexible parametric survival models in modeling multiple ...

The US Food and Drug Administration (FDA) has approved Shorla Oncology’s Imkeldi oral solution to treat certain forms of ...

The therapy can help patients combat myelodysplastic syndrome/myeloproliferative disease (MDS/MPD), gastrointestinal tumors (GIST) and cancers such as chronic myeloid leukemia (CML) and acute ...